The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors.
 
Chester Kao
No Relationships to Disclose
 
Eric Powers
No Relationships to Disclose
 
Michael B. Datto
No Relationships to Disclose
 
Michelle Green
Employment - N-of-One
 
Michael Roger Harrison
Consulting or Advisory Role - Argos Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Fujifilm; Genentech; Janssen Oncology; Pfizer; Sanofi
Speakers' Bureau - Exelixis; Genentech
Research Funding - Acerta Pharma (Inst); Argos Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech (Inst); Medivation/Astellas (Inst); Merck (Inst); Pfizer (Inst)
 
Andrew J. Armstrong
Honoraria - Dendreon; Janssen Oncology
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Janssen Biotech; Medivation; Pfizer; Sanofi
Speakers' Bureau - Bayer; Dendreon
Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc; Bayer; Dendreon; Janssen Biotech
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi
 
Jeffrey Melson Clarke
Consulting or Advisory Role - AstraZeneca; Guardant Health
Speakers' Bureau - Guardant Health; Lilly; Merck
Research Funding - Abbvie; Adaptimmune; Bristol-Myers Squibb; Genentech/Roche; medpacto; Moderna Therapeutics; Spectrum Pharmaceuticals
 
John H. Strickler
Stock and Other Ownership Interests - OncoMed
Honoraria - Chugai/Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Celgene; Genentech/Roche; OncoMed; Proteus Digital Health; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Cascadian Therapeutics (Inst); Exelixis (Inst); Gilead Sciences (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); MedImmune (Inst); Nektar (Inst); OncoMed (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Tian Zhang
Leadership - Capio BioSciences (I)
Stock and Other Ownership Interests - Capio Biosciences (I)
Honoraria - Exelixis; Genentech/Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Merck; Pfizer; Pharmacyclics; Sanofi; Seagen
Speakers' Bureau - Exelixis; Genentech/Roche; Genomic Health; Sanofi/Aventis
Research Funding - Acerta Pharma (Inst); Janssen (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Acerta Pharma; AstraZeneca; Genomic Health